EricS.DaarMD
Infectious Disease • Torrance, CAProfessor of Medicine, UCLA-David Geffen School of Medicine
Dr. Daar is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
1124 W Carson St., CDCRC 205
Division of HIV Medicine, Harbor-UCLA Medical Center
Torrance, CA 90502Phone+1 310-222-5101Fax+1 310-320-5463- Is this information wrong?
Education & Training
Cedars-Sinai Medical CenterFellowship, Infectious Disease, 1988 - 1991- Cedars-Sinai Medical CenterResidency, Internal Medicine, 1985 - 1988
Georgetown University School of MedicineClass of 1985
Certifications & Licensure
CA State Medical License 1986 - 2025- American Board of Internal Medicine Internal Medicine
Awards, Honors, & Recognition
- America's Top Doctors Castle Connolly, 2003-2014
- Top Doctors:LA Area Castle Connolly, 2013
- Top Doctors:Southern California Castle Connolly, 2012
- Join now to see all
Clinical Trials
- The Biology of HIV Transmission Start of enrollment: 1999 Oct 01
- Outcomes of Anti-HIV Therapy During Early HIV Infection Start of enrollment: 1999 Oct 01
- Effectiveness of Adding Remune to Your Current Anti-HIV Drug Combination
- Join now to see all
Publications & Presentations
PubMed
- 10 citationsSymptom and Viral Rebound in Untreated SARS-CoV-2 Infection.Rinki Deo, Manish C Choudhary, Carlee Moser, Justin Ritz, Eric S Daar, David A Wohl, Alexander L Greninger, Joseph J Eron, Judith S Currier, Michael D Hughes, Davey M ...> ;Annals of Internal Medicine. 2023 Mar 1
- Need for clear inclusion criteria in reviews of antiretroviral treatments - Authors' reply.Kevin M Gibas, Jose R Arribas, Pedro Cahn, Eric S Daar, Babafemi O Taiwo> ;The Lancet. HIV. 2023 Mar 1
- 3 citationsPhase 2 Safety and Antiviral Activity of SAB-185, a Novel Polyclonal Antibody Therapy for Nonhospitalized Adults With COVID-19.Babafemi O Taiwo, Kara W Chew, Carlee Moser, David Alain Wohl, Eric S Daar, Jonathan Z Li, Alexander L Greninger, Christoph Bausch, Thomas Luke, Keila Hoover, Gene Ney...> ;The Journal of Infectious Diseases. 2023 Jul 14
- Join now to see all
Journal Articles
- Substance Use and Adherence to HIV Preexposure Prophylaxis for Men Who Have Sex with Men1Jill S Blumenthal, Eric S Daar, Centers for Disease Control and Prevention
- Substance Use and Adherence to HIV Preexposure Prophylaxis for Men Who Have Sex with Men1Jill S Blumenthal, Eric S Daar, Centers for Disease Control and Prevention
- Safety and Impact of Low-Dose Methotrexate on Endothelial Function and Inflammation in Individuals with Treated Human Immunodeficiency Virus: AIDS Clinical Trials Grou...Steven G Deeks, James H Stein, Carl Fichtenbaum, Judith S Currier, Priscilla Y Hsue, Eric S Daar, Ahmed Tawakol, Michael Lederman, Tanvir Bell, Diane Havlir, Clinical Infectious Diseases
- Join now to see all
Other
- Evaluation of the treatment-experienced patient with drug-resistant HIV infectionDaar ES, Lagnese M
http://www.uptodate.com/contents/evaluation-of-the-treatment-experienced-patient-with-drug-resistant
UpToDate, Wolters Kluwer Health - 2012-12-21 - Selection of antiretroviral therapy for the treatment-experienced patient with drug-resistant HIV infectionDaar ES, Lagnese M
http://www.uptodate.com/contents/selection-of-antiretroviral-therapy-for-the-treatment-experienced-p
UpToDate, Wolters Kluwer Health - 2013-01-24
Authored Content
- Substance Use and Adherence to HIV Preexposure Prophylaxis for Men Who Have Sex with Men1November 2018
Press Mentions
Risks of Removing Ovaries at Benign Hysterectomy May Outweigh the Benefits for Women at Low Risk for Ovarian CancerApril 17th, 2023- At IDWeek, New Insights into Long COVIDOctober 21st, 2022
- ACTIV-2d, a Global Phase 3 Trial of Novel Investigational COVID-19 Oral Antiviral Agent, LaunchesAugust 22nd, 2022
- Join now to see all
Grant Support
- Clinical Trial: A Phase IIIB, Randomized, Trial Of Open-Label Efavirenz Or AtazaNational Center For Research Resources2010
- Clinical Trial: A Phase III Comparative Study Of Three Non-Nucleoside Reverse TRNational Center For Research Resources2010
- California Neuroaids Tissue Network (CNTN)National Center For Research Resources2010
- A Longitudinal Study Of Cerebral And Neurocognitive FunctionNational Center For Research Resources2009–2010
- Long-Term Metabolic Assessments In Subjects Treated With Emtricitabine/TenofoNational Center For Research Resources2007–2010
- California Neuro AIDS Tissue NetworkNational Center For Research Resources2004–2010
- A Phase II/III Randomized, Double-Blind, Placebo-Controlled TriaNational Center For Research Resources2009
- Clinical Trial: A Phase II/III Randomized, Double-Blind, Placebo-Controlled TriaNational Center For Research Resources2008
- Acute HIV Infection And Early Disease Research Program (AIEDRP)National Center For Research Resources2005–2008
- California Neuro - AIDS Tissue NetworkNational Center For Research Resources2004–2008
- Pathogenesis Of Primary HIV InfectionNational Center For Research Resources1998–2008
- The Setpoint Study - A Randomized Study Of The Effect Of Immediate TreatmentNational Center For Research Resources2007
- A Phase III, Randomized, Open-Label, Comparison Of Lopinavir/Ritonavir PLUS ENational Center For Research Resources2005–2007
- Phase III, Randomized, Open-Label, Comparison Of LopinNational Center For Research Resources2004
Hospital Affiliations
Harbor-UCLA Medical CenterTorrance, California
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
